Investing in the Future


Investing in the Future


MicMac Logo

Press Release | Micro-Macinazione S.A.

JULY 05, 2015

Molinazzo di Monteggio: – Micro-Macinazione, one of Europe’s leaders in the micronization of active pharmaceutical ingredients (APIs), is expanding its production and storage capacity and establishing new safety standards.

The Ticino-based company is investing CHF 3 million in a new banding system and in constructing new production units for the micronization of highly potent substances and cytotoxic products used in cancer treatment. Ultra-high safety standards (high containment) are demanded for the micronization of highly potent APIs, as production involves routine operations such as weighing, charging, discharging of powders which, are challenging and dangerous. Employees, the environment and the product must be adequately protected at all times, while simultaneously production must be able to take place as efficiently as possible. “That is why we decided to establish a new control banding system,” explains CEO Markus Arigoni. In this control process, each substance is assigned to a particular risk category. This defines the maximum concentration that may be present in the air, so as to ensure hazard-free product processing. Regular SMEPAC tests determine the concentration of airborne particulates. “This enables us to meet the very highest safety requirements at all stages of production,” declares Giovanna Libralon, Head of Business Development.

At the same time, Micro-Macinazione has a production unit for the micronization of highly potent substances and cytotoxic products used in the fight against cancer. “Our aim is to develop a new segregation strategy for certain pharmaceutical product classes and boost our production capacity in this area” says R&D Director Piero Iamartino.

To be able to meet growing customer demand, Micro-Macinazione is also investing in a new jet mill for the processing of very large volumes of highly active ingredients. The new equipment is made of innovative material, in order to improve its ergonomic profile and ensure containment of below 10
µg/m³.

In addition, Micro-Macinazione is constructing a new storage facility at its Molinazzo di Monteggio location. This will provide an extra 500 m2 of storage capacity for non-micronized and micronized materials. The building will comply with all GMP requirements, meet Micro-Macinazione’s increasing need for storage and help pave the way for further growth in the business.

About Micro-Macinazione SA

Micromacinazione SA was founded in 1970 in Molinazzo di Monteggio (Canton of Ticino, Switzerland) and is Europe’s leading provider in micronization of medical ingredients for the pharmaceutical industry. It is also a leader in designing and manufacturing the jet mills used in micronization and pneumatic conveyors. At its two sites, Molinazzo di Monteggio and Madonna del Piano, both in the canton of Ticino, the company employs some 115 staff and achieves sales of CHF 25 million a year. Both production sites are regularly inspected by the FDA and Swissmedic and have been certified by the Japanese Pharmaceuticals and Medical Devices Agency. It has some 200 clients, among them most of the global pharmaceutical companies.

Media Contacts

Published on behalf of Micro-Macinazione SA by:

KCCC Korfmann Corporate Communications Consulting AG Dr. Sabina R. Korfmann-Bodenmann
Chief Executive Officer
Zeltweg 40
CH-8032 Zurich
Tel. +41 43 244 87 37
Fax +41 43 244 87 38
E-Mail: s.korfmann@kccc.ch

Contact at Micro-Macinazione SA:

Giovanna Libralon
Head of Business Development
Via Cantonale 4
CH-6995 Molinazzo di Monteggio. Tel. +41 91 611 3636
Fax +41 91 611 3637
Mobile +41 76 5576201
E-Mail: glibralon@micromacinazione.com

Resources

Click on Investing in the Future for more information.
Click on Micro-Macinazione to contact the company directly.


Supplier Information
Supplier: Micro-Macinazione S.A.
Address: Via Cantonale 4 – 6995, Molinazzo di Monteggio, Switzerland
Tel: +41 (0)91 611 3636
Fax: +41 (0)91 611 3637
Website: www.micromacinazione.com


Comments are closed.